Despite the importance of metal cofactors, techniques to measure metal status in a proteomic fashion are not readily available. We have been focused on the development of tools that will allow the direct identification and quantitation of individual metalloproteins from biological samples. Application of metalloproteomics to amyotrophic lateral sclerosis(ALS) and Alzheimer’s disease has yield surprising insights in to the role of metalloproteins in both diseases. This has resulted in the first in-class clinical trial for ALS and Parkinson’s disease.  And a surprising insight into the iron and copper proteins involved in Alzheimer’s disease. Together the results presented will reinforce the essential role metalloproteins have in cellular function.